NCT00061646
Terminated
Phase 2
A Phase II Single-Arm Study Evaluating the Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Sponsor
- Abbott
- Enrollment
- 25
- Locations
- 4
- Primary Endpoint
- Progression free survival
- Status
- Terminated
- Last Updated
- 18 years ago
Overview
Brief Summary
The primary objective of this Phase II study is to assess the safety, pharmacokinetics and effectiveness of ABT-510 in combination with standard carboplatin/paclitaxel chemotherapy in subjects with stage IIIb or IV NSCLC.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Progression free survival
Time Frame: One year
Secondary Outcomes
- Overall survival(One year)
- Response rate(One year)
Study Sites (4)
Loading locations...
Similar Trials
Completed
Phase 2
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone SystemBone CancerBone MetastasesPainNCT01085565InSightec50
Recruiting
Phase 2
EUS-RFA PANCARDINAL-1 TrialPancreatic Ductal Adenocarcinoma (PDAC)NCT04990609The University of Texas Health Science Center, Houston60
Recruiting
Phase 2
Pembrolizumab Plus Radiotherapy for Advanced Renal CancerClear-cell Metastatic Renal Cell CarcinomaNCT05567588Nanfang Hospital, Southern Medical University66
Not Yet Recruiting
Phase 2
eoadjuvant Short course radiotherapy in esophageal carcinomaHealth Condition 1: C159- Malignant neoplasm of esophagus, unspecifiedCTRI/2020/12/029851AIIMS Rishikesh
Completed
Phase 2
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerTriple Negative Breast CancerBreast CancerNCT05112536G1 Therapeutics, Inc.24